Loading...
Advanced Hepatocellular cancer (HCC) is common globally and is becoming more common in the U.S. due to the increasing prevalence of hepatitis C virus infection. The standard of care for advanced HCC is sorafenib, a tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptor, RAF, and other tyrosine kinases. To determine the potential benefit of chemotherapy in this setting, international investigators conducted a phase III, multicenter, randomized, open-label trial (EACH), comparing doxorubicin with FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) in 371 Asian patients with advanced HCC.
Patients received either doxorubicin (50 mg/m2) once every 3 weeks or oxaliplatin (85 mg/m2 on day 1), leucovorin (…